MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2–Positive and/or Hormone Receptor–Negative Breast Cancers in the I-SPY 2 Trial

PURPOSE: The phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin is a key pathway of survival and therapeutic resistance in breast cancer. We evaluated the pan-Akt inhibitor MK-2206 in combination with standard therapy in patients with high-risk early-stage breast cancer. PATIENTS AND ME...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Chien, A. Jo, Tripathy, Debasish, Albain, Kathy S., Symmans, W. Fraser, Rugo, Hope S., Melisko, Michelle E., Wallace, Anne M., Schwab, Richard, Helsten, Teresa, Forero-Torres, Andres, Stringer-Reasor, Erica, Ellis, Erin D., Kaplan, Henry G., Nanda, Rita, Jaskowiak, Nora, Murthy, Rashmi, Godellas, Constantine, Boughey, Judy C., Elias, Anthony D., Haley, Barbara B., Kemmer, Kathleen, Isaacs, Claudine, Clark, Amy S., Lang, Julie E., Lu, Janice, Korde, Larissa, Edmiston, Kirsten K., Northfelt, Donald W., Viscusi, Rebecca K., Yee, Douglas, Perlmutter, Jane, Hylton, Nola M., van’t Veer, Laura J., DeMichele, Angela, Wilson, Amy, Peterson, Garry, Buxton, Meredith B., Paoloni, Melissa, Clennell, Julia, Berry, Scott, Matthews, Jeffrey B., Steeg, Katherine, Singhrao, Ruby, Hirst, Gillian L., Sanil, Ashish, Yau, Christina, Asare, Smita M., Berry, Donald A., Esserman, Laura J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2020
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7106976/
https://ncbi.nlm.nih.gov/pubmed/32031889
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.01027
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados